Blog

Greenway DNA: Leveraging DNA to Solve the Dosing Challenge in Natural Medicine

Dec 11 • 7 min read

One of the significant challenges in psychedelic medicine is effectively personalizing dosage. The process today relies on a lot of imprecision—to the detriment of the patient. And that translates to lost opportunities for patients, clinicians, and psychedelic medicine as a whole. Greenway DNA is developing individual genetic tests to resolve that imprecision, using genetic variants…

Better Plant Subsidiary NeonMind Announces Filing of Final Prospectus in Connection with an Initial Public Offering

Dec 11 • 6 min read

Better Plant Sciences Inc. announced that its majority-owned subsidiary NeonMind Biosciences Inc. obtained a receipt for a final prospectus for an initial public offering.

Tryp Therapeutics Files Final Prospectus and Announces Initial Public Offering

Dec 10 • 4 min read

Tryp Therapeutics Inc. announced that it has obtained a receipt for its final prospectus in connection with the initial public offering

Red Light Holland Announces Intention to Acquire Controlling Interest in Psychedelic Insights Providing Psychological Guidance of Psychedelic Experiences with Truffles in the Netherlands

Dec 9 • 4 min read

Quick Take: Red Light Holland Corp has entered into a non-binding letter of intent to acquire 51% of Psychedelic Insights A condition in the agreement will include: an exclusive supply agreement with Red Light Holland’s Truffles with the intention to be used solely by Psychedelic Insights’ clients. Toronto, Ontario–(Newsfile Corp. – December 9, 2020) –…

Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs Inc. Completion of Initial DMT Research Drug Batch

Dec 9 • 4 min read

Quick Take: Entheon Biomedical Corp. announced it has entered into a drug-supply agreement with Psygen Labs Inc. The agreement provides Entheon with DMT drug material for preliminary formulation, stability and testing required prior to its forthcoming human clinical trial, scheduled to begin in Q4 2021 Entheon shareholders have also exercised an aggregate 533,359 warrants at…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548